Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q2 2020 Earnings Conference Call August 10, 2020 8:30 AM ET Company Participants Lisa Wilson - IR Scott Tarriff - CEO Pete Meyers - CFO David Pernock - President and COO Conference Call Participants Randall Stanicky - RBC Capital Markets David Amsellem - Piper Sandler Brandon Folkes - Cantor Fitzgerald Operator Good morning, and welcome to today's program. My name is Keith, and I'll be your conference operator. At this time, I'd like to welcome everyone to Eagle Pha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ____________ Commission File Number 001-36306 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 20-8179278 (S ...

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q1 2020 Results Earnings Conference Call May 11, 2020 8:30 AM ET Company Participants Lisa Wilson - Investor Relations Scott Tarriff - Chief Executive Officer Pete Meyers - Chief Financial Officer David Pernock - President and COO Adrian Hepner - our Chief Medical Officer Conference Call Participants Tim Lugo - William Blair Dan Busby - RBC Capital Markets Brandon Folkes - Cantor Fitzgerald Operator Good morning, and welcome to today's program. My name is Keith, and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or | --- | --- | --- | |----------------------------------------------------|------------------------------------------------------------------------------------------------------|-------------------------------| | | | | | | | | | | For the transition period from to . | | | | Commission ...

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q4 2019 Results Conference Call March 2, 2020 8:30 AM ET Company Participants Lisa Wilson - IR Scott Tarriff - CEO Pete Meyers - CFO Conference Call Participants Zach Sachar - Piper Sandler Randall Stanicky - RBC Capital Markets Lachlan Hanbury-Brown - William Blair Brandon Folkes - Cantor Fitzgerald Gregg Gilbert - SunTrust Operator Good day, and welcome to today's program. My name is Brie, and I'll be your conference operator. At this time, I'd like to welcome eve ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ____________ Commission File Number 001-36306 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 20-817927 ...

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q3 2019 Earnings Conference Call November 12, 2019 8:30 AM ET Company Participants Lisa Wilson - Investor Relations Scott Tarriff - Chief Executive Officer Pete Meyers - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Randall Stanicky - RBC Capital Markets Lachlan Hanbury-Brown - William Blair Operator Good day, and welcome to today's program. My name is Keith, and I'll be your conference operator. At this time, I'd like to w ...

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q2 2019 Earnings Conference Call August 8, 2019 8:30 AM ET Company Participants Lisa Wilson - IR Scott Tarriff - CEO & Director Pete Meyers - CFO Conference Call Participants Ashley Ryu - RBC Capital Markets Brandon Folkes - Cantor Fitzgerald Operator Good day, and welcome to today's program. My name is Keith, and I'll be your conference operator today. At this time, I'd like to welcome everyone to Eagle Pharmaceuticals Second Quarter 2019 Earnings Results Conferenc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ____________ Commission File Number 001-36306 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 20-8179278 (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ____________ Commission File Number 001-36306 Eagle Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 20-8179278 (S ...